Cidara Theraptcs SEC Filings

Cidara Therapeutics investor Bain Capital Life Sciences entity reports no current stake in the company’s common stock. An Amendment No. 3 to Schedule 13G/A filed by BCLS Fund III Investments, LP states that, as of December 31, 2025, it beneficially owned 0 shares, representing 0% of Cidara’s outstanding common stock. The filing confirms the reporting person has no sole or shared voting or dispositive power over any Cidara shares and that any securities referenced are not held for the purpose of changing or influencing control of the issuer.

Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman Fund, L.P. and their related LLCs filed an amended Schedule 13G stating they no longer own any common stock of Cidara Therapeutics, Inc. Following completion of the issuer’s merger on January 7, 2026, each reporting person shows 0 shares beneficially owned and 0% of the class, with no voting or dispositive power remaining.

The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Cidara Therapeutics Inc common stock. Vanguard reports beneficial ownership of 2,007,193 shares, representing 6.38% of the outstanding common stock as of the event date.

Vanguard has shared voting power over 176,207 shares and shared dispositive power over 2,007,193 shares, with no sole voting or dispositive power. The holdings are for clients, none of whom individually exceeds 5% of the class. Vanguard states the shares are held in the ordinary course of business and not to change or influence control. Vanguard also notes an internal realignment on January 12, 2026, after which certain subsidiaries may report ownership separately.

RA Capital Healthcare Fund, advised by RA Capital Management, fully exited its Cidara Therapeutics (CDTX) position in connection with Merck’s acquisition. Pre-funded warrants for 1,286,786 common shares were cashless exercised into common stock immediately before the merger. The Fund then disposed of 4,652,309 Cidara common shares at $221.50 per share in the tender offer. It also disposed of 89,956 Series A Preferred shares, which were exchanged for $15,505.00 per Series A share under the merger terms.

Outstanding stock options covering 22,200 and 5,079 common shares became fully vested and were cancelled at the merger’s effective time in return for cash based on the $221.50 per-share merger price minus the applicable exercise prices. The Form 4 notes that the reported securities are held by the Fund and that RA Capital entities and principals disclaim beneficial ownership except for their pecuniary interests.

RA Capital Management and its affiliates filed an amended Schedule 13D showing they no longer beneficially own any shares of Cidara Therapeutics, Inc. Each reporting person now reports 0.00 shares and 0.0% of Cidara’s common stock, with no sole or shared voting or dispositive power. The amendment explains that a tender offer for Cidara’s shares expired on January 6, 2026, after which the buyer accepted all validly tendered shares and then completed a merger on January 7, 2026.

Following the merger, Cidara became a wholly owned subsidiary of the acquiror, its common stock was deregistered under the Exchange Act, and it ceased trading on the Nasdaq Stock Market. RA Capital’s fund had tendered all of its common and Series A shares, and its pre-funded warrants were cashlessly exercised and converted into the right to receive the cash offer price, leaving the reporting persons with no remaining beneficial ownership.

Cidara Therapeutics director reports option cancellation tied to Merck buyout. On January 7, 2026, a Merck subsidiary completed a tender offer for all outstanding Cidara common and Series A preferred shares and then merged into Cidara, which continues as a wholly owned Merck subsidiary. In connection with the merger, each outstanding stock option became fully vested and, if unexercised, was cancelled at the merger’s effective time and converted into a cash right equal to the number of underlying shares multiplied by the excess of $221.50 per share over the option’s exercise price.

The Form 4 reports that director Joshua Resnick had stock options covering 22,200 and 5,079 Cidara common shares, both reported as derivative dispositions leaving zero options outstanding. The filing notes these options are held for the benefit of RA Capital Healthcare Fund, and Resnick is required to turn over any net cash or stock to RA Capital Management, so he disclaims beneficial ownership of the options and underlying shares.

Cidara Therapeutics director Spencer Ryan reported the cash-out of his stock options in connection with Merck’s acquisition of the company. Under a Merger Agreement dated November 13, 2025 among Cidara, Merck Sharp & Dohme LLC and Caymus Purchaser, Inc., a tender offer for all outstanding common and Series A preferred shares was completed on January 7, 2026 and followed by a merger, making Cidara a wholly owned subsidiary of Merck.

Immediately before the effective time of the merger, each of Ryan’s outstanding stock options became fully vested and exercisable and, to the extent unexercised, was cancelled and converted into a right to receive cash. The cash amount equals the number of common shares subject to each option multiplied by the excess of $221.50 per share over the option’s exercise price. The Form 4 lists option grants with exercise prices of $12.63, $12.64 and $21.31 per share, all reduced to zero balance after the transaction.

Cidara Therapeutics director James Merson reported the cash cancellation of stock options tied to Merck’s acquisition of Cidara. On January 7, 2026, a Merck subsidiary completed a tender offer for all outstanding Cidara common shares and Series A preferred shares and then merged into Cidara, which became a wholly owned Merck subsidiary. In connection with the merger, each of Merson’s outstanding stock options, including grants over 4,250, 2,125 and 11,100 Cidara common shares, became fully vested and exercisable and was then cancelled.

Each cancelled option was converted into the right to receive cash, without interest and subject to tax withholding, equal to the number of underlying shares multiplied by the excess of $221.50 per share over the option’s exercise price.